DÄ internationalArchive13/2007Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Germany

Original article

Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Germany

Dtsch Arztebl 2007; 104(13): A-861

Berthold, H K; Gouni-Berthold, I; Bestehorn, K; Böhm, M; Krone, W

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34. MEDLINE
2. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H: A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia 1990; 33: 542–8. MEDLINE
3. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000; 23 Suppl 1: S32–42. MEDLINE
4. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486–97. MEDLINE
5. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB et al.: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110: 227–39. MEDLINE
6. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335–42. MEDLINE
7. Lehnert H, Wittchen HU, Pittrow D, Bramlage P, Kirch W, Bohler S et al.: Prevalence and pharmacotherapy of diabetes mellitus in primary care. Dtsch Med Wochenschr 2005; 130: 323–8. MEDLINE
8. Krone W, Bohm M: Diabetes mellitus needs unrestricted evaluation of patient data to yield treatment progress. The DUTY Register. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 47: 540–6. MEDLINE
9. Bestehorn K: Medical registries. Med Klin (Munich ) 2005; 100: 722–8. MEDLINE
10. Bergenstal RM, Nag SS, Reusch JE, Sajjan SG, Alexander CM: Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. Endocr Pract 2005; 11: 172–9. MEDLINE
11. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20. MEDLINE
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53. MEDLINE
13. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62. MEDLINE
14. Moser M, Setaro JF: Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355: 385–92. MEDLINE
15. Singer GM, Izhar M, Black HR: Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40: 464–9. MEDLINE
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16. MEDLINE
17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96. MEDLINE
18. Diabetes Control and Complications (DCCT) Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–86. MEDLINE
19. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C: The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complications 2006; 20: 75–80. MEDLINE
20. Seufert J: Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2-Diabetes-mellitus. Dtsch Arztebl 2006; 103: A934–42. VOLLTEXT
21. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M et al.: Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006; 152: 27–38. MEDLINE
22. Kuehn BM: „Polypill“ could slash diabetes risks. JAMA 2006; 296: 377–80. MEDLINE
e1. Leitlinien der Deutschen Diabetes Gesellschaft. http://www.ddg.info
e2. Bundes­ärzte­kammer, Arznei­mittel­kommission der deutschen Ärzteschaft, Deutsche Diabetes Gesellschaft, Fachkommission Diabetes Sachsen, Deutsche Gesellschaft für Innere Medizin, AWMF: Ärztliche Zentralstelle Qualitätssicherung (Hrsg.): Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2. Nationales Programm für die Versorgungs-Leitlinien bei der Bundes­ärzte­kammer. 2002. http://www.versorgungsleitlinien.de/themen/pdf/nvldiabetes.pdf
e3. Arznei­mittel­kommission der deutschen Ärzteschaft: Therapieempfehlungen zum Diabetes mellitus Typ 2. Arzneiverordnung in der Praxis Supplement. 2002. http://www.akdae.de/35/85_Diabetes_ 2002_1Auflage.pdf
e4. Ärztliches Zentrum für Qualität in der Medizin: http://www.aezq.de/
e5. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes. Diabetes Care 1999; 22: 1887–98. MEDLINE
e6. Colwell JA: Aspirin therapy in diabetes. Diabetes Care 1997; 20: 1767–71. MEDLINE
e7. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160–78. MEDLINE
e8. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134–47. MEDLINE
e9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–72. MEDLINE
e10. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–13. MEDLINE
e11. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412–9. MEDLINE
e12. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9. MEDLINE
e13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–57. MEDLINE
e14. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16. MEDLINE
e15. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53. MEDLINE
e16. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–65. MEDLINE
e17. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381–9. MEDLINE
e18. Selvin E, Marinopoulos S, Berkenblit G et al.: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31. MEDLINE
e19. Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (Suppl): 830. MEDLINE
e20. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 1975; 24 (Suppl 1): 65–184. MEDLINE
e21. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982; 31(Suppl 5): 1–81. MEDLINE
e22. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17. MEDLINE
e23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–65. MEDLINE
e24. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–93. MEDLINE
e25. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647–53. MEDLINE
e26. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89. MEDLINE

Info

Specialities